A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson’s Disease Patients

checkorphan
Learn more about:
Wilson disease
Related Clinical Trial
Gandouling in the Treatment of Wilson’s Disease International Wilson’s Disease Patient Registry (iWilson Registry) Wilson France Register Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease Clinical Features and Outcome of Wilson’s Disease With Generalized Epilepsy in Chinese Patients Role for Biochemical Assays and Kayser-Fleischer Rings in Diagnosis of Wilson Disease rTMS in Wilmson Diasease Dysarthria Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840 A Phase I/II Study of VTX-801 in Adult Patients With Wilson’s Disease Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants. Clinical Evaluation and Assessment of Instruments and Biomarkers in Subjects With Wilson Disease Copper Concentration and Histopathologic Changes in Liver Biopsy in Participants With Wilson Disease Treated With ALXN1840 Study of Retinal Vascular Parameters in Patients With Wilson’s Disease Evaluation of Patients With Liver Disease ExAblate Transcranial MRgFUS for the Management of Treatment-Refractory Movement Disorders The Assessment of Copper Parameters in Wilson Disease Subjects on Standard of Care Treatment Establishment of Human Cellular Disease Models for Wilson Disease Efficacy and Safety, Long-term Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson’s Disease-related Liver Failure The Individual Therapy for Patients With Wilson’s Disease Study of Zinc for Wilson Disease Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson’s Disease Study of Tetrathiomolybdate in Patients With Wilson Disease Efficacy and Safety of ALXN1840 (Formerly Named WTX101) Administered for 48 Weeks Versus Standard of Care in Patients With Wilson Disease With an Extension Period of up to 60 Months WILSTIM – DBS (WILson STIMulation – Deep Brain Stimulation) Efficacy and Safety Study of Zinc Acetate to Treat Wilson’s Disease in Japan. Efficacy of Invitro Expanded Bone Marrow Derived Allogeneic Mesenchymal Stem Cell Transplantation Via Portal Vein or Hepatic Artery or Peripheral Vein in Patients With Wilson Cirrhosis Inhibitory rTMS in Dystonic Wilson Patients Natural History of Wilson Disease A Registered Cohort Study on Wilson’s Disease sCD163 and sMR in Wilsons Disease – Associations With Disease Severity and Fibrosis Cohort Research on Wilson’s Disease Single Daily Dosage of Trientine for Maintenance Treatment for Wilson Disease A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson’s Disease Patients Efficacy and Safety Study of WTX101 in Adult Wilson Disease Patients

Brief Title

A Phase 1 Study to Assess the Effects in the Body of a Single Dose of Trientine Dihydrochloride in Wilson's Disease Patients

Official Title

A Phase 1 Pharmacokinetic Profiling Study in Patients Receiving Trientine Dihydrochloride for the Treatment of Wilson's Disease.

Brief Summary

      To evaluate the effects of a single dose of trientine in children ≥6 years and adult patients
      with Wilson's disease.

Detailed Description

      An open, single-dose study to determine the pharmacokinetics, and safety of oral
      administration of trientine dihydrochloride in both children and adult patients with Wilson's
      Disease. Blood samples will be taken pre-dose and at 10 time-points post-dose to investigate
      the pharmacokinetic profile of trientine dihydrochloride up to 12 hours after intake of study
      medication in 20 patients.

Study Phase

Phase 1

Study Type

Interventional

Primary Outcome

Pharmacokinetic measurements

Condition

Wilson's Disease

Intervention

trientine dihydrochloride

Study Arms / Comparison Groups

 Trientine dihydrochloride
Description:

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Drug

Estimated Enrollment

20

Start Date

May 2013

Completion Date

March 2014

Primary Completion Date

March 2014

Eligibility Criteria

        Inclusion Criteria:

          1. Children ≥ 6 years and adult patients

          2. Confirmed diagnosis of Wilson's disease by Leipzig-Score >3 (Ferenci et al 2003)

          3. Current treatment with trientine dihydrochloride

          4. Signed informed consent including parental consent in patients ≤ 18 years

          5. Agree to remain in the study site1 for the PK measurements period.

        Exclusion Criteria:

          1. Known clinically significant allergy or hypersensitivity to drugs that, in the opinion
             of the investigator, may affect the patient's safety

          2. Have any clinically significant conditions that would interfere with the collection or
             interpretation of the study results or would compromise the patient's health

          3. Women of child bearing potential who do not use contraceptives, breastfeeding, or
             pregnant women

          4. Severe anaemia (haemoglobin <9 mg/dL)

          5. In the judgment of the Investigator, is likely to be noncompliant or uncooperative
             during the study, or unable to cooperate because of a language problem or poor mental
             development

          6. Participation in any interventional clinical study at the same time or within the 4
             weeks prior his study.

Gender

All

Ages

6 Years - 90 Years

Accepts Healthy Volunteers

No

Contacts

, ,

Location Countries

Germany

Location Countries

Germany

Administrative Informations

NCT ID

NCT01874028

Organization ID

TR-001PK

Responsible Party

Sponsor

Study Sponsor

Univar BV

Collaborators

 Aptiv Solutions

Study Sponsor

, ,

Verification Date

September 2014